LAWRENCE, MA — Biomanufacturing firm Revvity Inc. (NYSE: RVTY), one of Massachusetts’ largest public companies, is continuing its workforce reduction efforts, confirming the closure of a second site in the state and additional layoffs. The news was first reported by the Boston Business Journal (BBJ).
According to a Worker Adjustment and Retraining Notification (WARN) filed with the state, Revvity will permanently shut down its Lawrence facility at 360 Merrimack St., impacting 51 employees. While some staff may be offered transfers to the company’s Hopkinton campus, layoffs are expected to begin as early as December 2025, with the majority occurring by January 2026, BBJ reported.
This development comes just weeks after Revvity disclosed the upcoming closure of its Boston South End facility at 549 Albany St., where 74 jobs are set to be cut, as previously noted by BBJ. Those layoffs are scheduled to roll out between November 2025 and December 2026.
A company spokesperson told BBJ that the move is part of a broader effort to “consolidate operations from our Lawrence and Boston sites into our Hopkinton campus to streamline our footprint.” The spokesperson added that most employees at the affected sites are being offered relocation opportunities, and emphasized Revvity’s commitment to supporting staff through the transition while maintaining a strong presence in Massachusetts.
From Spin-Out to Streamlining
Revvity, a spin-out of PerkinElmer Inc., is the 35th largest public company in Massachusetts, with 759 in-state employees as of April 2025, per BBJ’s research. Globally, the company employs around 11,000.
Revvity’s core operations include biomarker identification, diagnostics, imaging, informatics, and predictive technologies — areas crucial to the future of personalized medicine and biotech innovation.
But despite its strategic focus, the company has been under financial pressure: Revvity’s stock has fallen more than 26% since the start of 2025, and it closed Friday with a market cap of $10.64 billion, BBJ said.
The consolidation reflects a growing trend in the biomanufacturing and biotech sectors: rationalizing physical footprints in favor of operational efficiency, especially amid tightening capital markets and broader economic uncertainty.
While Revvity emphasized its continued commitment to Massachusetts, the closures represent a significant change in the state’s biotech employment landscape. As one of the Commonwealth’s key industries, biomanufacturing layoffs often have ripple effects across local economies and supply chains.
The Boston Business Journal noted that the majority of job transitions will occur in the first quarter of 2026, but some affected employees could see impacts beginning next month.
Revvity has not yet announced whether additional restructuring is planned beyond the current site consolidations.
This article is based on original reporting by the Boston Business Journal (BBJ). Read the full report here
